Pulmonx Corporation Common Stock (LUNG) is a publicly traded Healthcare sector company. As of May 21, 2026, LUNG trades at $1.54 with a market cap of $55.33M and a P/E ratio of -1.16. LUNG moved +15.67% today. Year to date, LUNG is -31.25%; over the trailing twelve months it is -54.03%. Its 52-week range spans $1.13 to $9.37. Analyst consensus is strong buy with an average price target of $3.50. Rallies surfaces LUNG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Pulmonx Q1 Revenue Drops 9% to $20.6M, Margin Rises to 78%: Pulmonx’s Q1 2026 revenue totaled $20.6M, down 9% y/y (12% constant currency), with U.S. sales at $13.3M (−7%) and international revenue $7.3M (−12%, +22% excluding China). Gross margin improved to 78%, and net loss narrowed to $13.7M, or $0.33 per share.
| Metric | Value |
|---|---|
| Price | $1.54 |
| Market Cap | $55.33M |
| P/E Ratio | -1.16 |
| EPS | $-1.30 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.37 |
| 52-Week Low | $1.13 |
| Volume | 15 |
| Avg Volume | 0 |
| Revenue (TTM) | $88.55M |
| Net Income | $-53.21M |
| Gross Margin | 75.49% |
4 analysts cover LUNG: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $3.50.